AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01699763 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Contour® NEXT LINK BGMS
Description: Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with and without diabetes (up to 10% of subjects without diabetes were included). Performance of Contour® NEXT LINK BGMS was evaluated across the glucose range of the BGMSs. All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
Study NCT01699763 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OneTouch® UltraLink® BGMS
Description: Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with and without diabetes (up to 10% of subjects without diabetes were included). Performance of OneTouch® UltraLink® BGMS was evaluated across the glucose range of the BGMSs. All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
Study NCT01699763 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nova Max Link® BGMS
Description: Study staff performed Blood Glucose (BG) tests with capillary fingerstick blood collected from subjects with and without diabetes (up to 10% of subjects without diabetes were included). Performance of Nova Max Link® BGMS was evaluated across the glucose range of the BGMSs. All meter BG results were compared with capillary plasma results obtained with a reference laboratory glucose method (YSI Glucose Analyzer).
Study NCT00390702 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcatheter implantation of a VSD occluder (Nitinol coil)
Description: transcatheter implantation, by first performing a arterial-venous loop through the defect
Study NCT03138447 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Basal Insulin Titration Application
Description: Healthcare Providers (HCP) and the principal investigator (PI) will use an HCP portal to initiate a basal insulin titration algorithm. HCPs can customize the titration algorithm for every participant. Once a participant is prescribed an algorithm, they can download a mobile app on their phone with their HCPs corresponding titration plan. The app will prompt participants to enter their fasting glucose daily. Based on their fasting glucose and their HCPs titration plan, the application will display the participants daily basal insulin dose.
Study NCT04851431 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: one-to-one peer mentoring
Description: Weekly meetings with a peer family caregiver
Study NCT04851431 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: one-to-one peer mentoring
Description: Weekly meetings with a peer family caregiver
Study NCT01183325 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Proceed Ventral Patch placement
Description: Placement of a Proceed Ventral Patch for umbilical and small ventral hernias less than 3cm diameter with and without laparoscopic control
Study NCT01524302 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ceftaroline
Description: 600 mg Q12h
Study NCT01524302 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levofloxacin
Description: 750 mg QD
Study NCT04313049 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: JACO2
Description: Performing tasks using joystick control
Study NCT04313049 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JACO2
Description: Performing tasks using joystick control
Study NCT04313049 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VOCAL CONTROL
Description: Performing tasks using vocal control
Study NCT00753220 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VDC2008
Description: Intratumoral injection of VDC2008 post-cryotherapy.~Dosage will depend on cohort: 2.5 x 10\^7, 7.5 x 10\^7 or 1.0 x 10\^8 cells
Study NCT00753220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide i.v. given at day -3 (dose: 300mg/m2); Low-dose Cyclophosphamide pill given twice daily (dose: 25 mg, p.o., b.i.d. for 7 days on and 7 days off; a total of 6 cycles \[1 cycle = 4 weeks\] starting Week 2 after cryoablation and going to Week 26)
Study NCT02370225 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aerobic exercise
Description: Each training session was preceded by a warm-up period, where patients were instructed to walk freely and slowly for 5 minutes, followed by 20 to 50 minutes of effective walking when they were instructed to maintain their paces to achieve the target heart rate and ending by a cold-up period for 5 minutes (similar to warm-up period).~The exercise prescription was based on the heart rate at the anaerobic threshold determined at the initial assessment. The increment of intensity exercise was based on time: 30 in the first 2 weeks, adding 5 minutes per week until eighth week, completing 60 minutes, which remains until the end.
Study NCT02395978 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Placebo contained corn starch.
Study NCT02395978 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo contained corn starch.
Study NCT03602963 — intervention group
Intervention type: DEVICE
Intervention: Dexcom G5 Mobile CGM system
Description: The accuracy and usability ot the Dexcom G5 mobile CGM system will be evaluated
Study NCT00192270 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAIV-T
Description: Each dose of the vaccine was formulated to contain approximately 1 x 10\^7 TCID50 of each of three (two subtype A and one subtype B) reassortant 6:2 influenza strains, as described above, for a total of \~3 x 10\^7 TCID50 per dose.
Study NCT03921151 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Mirtazapine 15 MG Oral Tablet
Description: The intervention will be a 15mg of mirtazapine oral tablet given to participants prior to their treatment scan and assessments. In order to ensure that biases or social desirability do not contaminate baseline assessments, all participants will also be given a tablet consisting of dextrose in gelatin prior to their baseline scan and assessment.
Study NCT03343613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3381916
Description: IDO-1 inhibitor administered orally
Study NCT03343613 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3300054
Description: PD-L1 inhibitor administered IV
Study NCT01896908 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sodium restriction
Description: Patients that are eligible and fulfill the inclusion criteria will be invited to participate while hospitalized, and then sign the informed consent form. Then, the dietitian on call will be notified in order to change the dietary map of the patients. The prescription diet for both the intervention and control group will be the same: DIET AS RESEARCH PROTOCOL. PATIENT WILL RECEIVE THE DIET UNTIL DAY __ / __ OR DISCHARGE. PLEASE DO NOT CHANGE IT. This will be combined with the medical staff and with the Nutrition and Dietetics service.~The evaluation of outcomes after hospital discharge will be held in the institution of reference when will be performed clinical evaluation and blood samples collection for neurohormonal activation analysis.
Study NCT01615796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part A: GSK2140944 Drug single dose of 200mg, 600mg, 1200mg, 1800 mg, and dose to be determined
Description: Subjects receive a single dose of GSK2140944
Study NCT05104294 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Optical Coherence Tomography- Angiography
Description: Peripapillary retinal nerve fiber layer thickness, ganglion cell complex, superficial and deep capillary plexus vessel density were measured.
Study NCT01615796 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part B: GSK2140944 Repeat Drug dose of 400mg, 750mg, 1000 mg, and dose to be determined
Description: Subjects will receive repeat doses of GSK2140944 BID/TID for up to 14 Days
Study NCT04345406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACEIs
Description: Captopril or enalapril
Study NCT04345406 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Conventional treatment
Description: alexoquine
Study NCT01354041 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy
Description: Seven weekly sessions of Acceptance and Commitment Therapy (ACT) intervention
Study NCT03532581 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Indocyanine Green Solution
Description: Given Subcutaneous injection
Study NCT05104294 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Photopic negative response
Description: Both the implicit time and amplitude of PhNR were recorded.
Study NCT00011986 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Given IV
Study NCT00011986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given IV
Study NCT00011986 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Given IV
Study NCT00011986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV
Study NCT03532581 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lymphangiography
Description: Undergo lymphangiography
Study NCT02952703 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: brief pre-delivery smoking cessation counseling
Study NCT02952703 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: additional pre-delivery smoking cessation counseling
Study NCT02952703 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: post- delivery smoking cessation counseling
Study NCT02952703 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: incentives
Study NCT03372668 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: massage therapy combined with components of mirror therapy
Description: Individualized 20-minute, Swedish massage to address participant's unique phantom limb pain experience as if occurring on the corresponding, non-amputated limb. A specially designed apparatus is positioned such that a fixed, real-time image in place of the amputated limb is viewed by the participant during the massage session. The apparatus has a mirror, masking material to hide therapist and participant's lower body, electronic video display, electronic video camera, and equipment to electronically communicate the video signal to the video display. The mirror and video camera positioned to see a reflection of the existing limb being massage feds the image to a live video display situated in front of the participant to the correct orientation naturally represent the missing limb.
Study NCT01807260 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Shock wave lithotripsy
Description: All procedures were performed under continuous intravenous sedo-analgesia (using a combination of ketamine 1 mg/kg and propofol 0,5-1 mg/kg) with fluoroscopic or ultrasonograpic imaging in a supine position. Shock wave lithotrpisy was poerformed with a Dornier Compact Delta lithotripter (Dornier Medtech, Germany). Shock wave number was limited to a maximum of 3000 waves/session. In the conventional group the voltage was only 13 kV. The stone burden was defined as the stone area that was calculated by multiplying the largest length and width of the individual stones measured from the abdominal plain X-ray.
Study NCT01106742 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: AndoSan
Description: AndoSan, 20mlx3, 12 days
Study NCT02539355 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diet A
Description: 12-week diet
Study NCT02539355 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet B
Description: 12-week Diet
Study NCT03933514 — intervention group
Intervention type: OTHER
Intervention: Plaque control
Description: Children were instructed about the hygiene procedures
Study NCT00664950 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: sliding hip screw
Description: surgical repair of hip fracture using conventional sliding hip screw
Study NCT00664950 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IntertAn IM nail
Description: interTAN IM nail
Study NCT03737045 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Decision Aid
Description: Participants will test decision aid prototypes that are designed to assist them in choosing a medication.
Study NCT03749798 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cataract surgery
Description: Intraoperative wavefront measurements will be carried out during cataract surgery
Study NCT00485589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Oral repeating dose
Study NCT00485589 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocrelizumab
Description: Intravenous repeating dose
Study NCT00485589 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous repeating dose
Study NCT02155361 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topical Citrullus colocynthis fruit oil (1%)
Study NCT02155361 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Topical vehicle oil
Study NCT03106948 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subject will undergo endoluminal biopsy prior to angioplasty but will NOT undergo insertion of the ACT drug delivery catheter
Study NCT03106948 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ascorbic Acid
Description: Subject will undergo endoluminal biopsy prior to angioplasty followed by insertion of the ACT drug delivery catheter where ascorbic acid (10.0 µM) will be injected following conventional balloon angioplasty
Study NCT03106948 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cuprimine Oral Product
Description: Subject will undergo endoluminal biopsy prior to angioplasty followed by insertion of the ACT drug delivery catheter where ascorbic acid (10.0 µM) in combination with D-penicillamine (25 µM) will be injected following conventional balloon angioplasty
Study NCT03387956 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intrathecal atropine
Description: 100ug intrathecal atropine will be injected with spinal anesthesia
Study NCT03387956 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone
Description: intravenous 8 mg dexamethasone (2ml).
Study NCT03054987 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: EUS-BD
Description: EUS-BD is a minimally invasive technique where the common bile duct (choledochoduodenostomy) is punctured under EUS-guidance and after transmural dilation, a stent is deployed for biliary drainage.
Study NCT03054987 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ERCP
Description: During the ERCP, a small catheter and guidewire is inserted into the bile duct and the stent can be deployed into the duct.
Study NCT00980785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramipril
Description: Ramipril 5 mg/day
Study NCT00980785 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching Placebo
Study NCT02433860 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: pharmacist nicotine cessation counseling using SCRIPT protocol
Description: Participant will be shown a short DVD Commit to Quit: During and After Pregnancy. She will be given a Pregnant Woman's Guide to Quitting booklet.~Participant will be asked their nicotine use status and it will be confirmed with a CO meter test and cotinine urine test. Those not consenting to be part of the study will not receive the urinalysis.~Participant will be advised to quit smoking. The pharmacist will review the Guide with the participant. The participant will receive a phone call around the time of their quit/reduction date. The participant will meet again approximately one week after their quit/reduction date and receive a CO meter test and urine cotinine test.~At the end of the program pregnant women will answer a follow-up questionnaire. Those women participating in the research study will be given a cotinine urine test at approximately > 36 weeks gestation or at delivery.
Study NCT00658710 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: physical therapy sessions
Description: two physical therapy sessions per week for two months
Study NCT01061736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sarilumab
Description: Pharmaceutical form: solution for injection~Route of administration: subcutaneous
Study NCT02677181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATG
Description: rabbit ATG（Sanofi）
Study NCT02677181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CsA
Description: cyclosporine (3 mg/kg, q12h, i.v.) was used from day -9, and the concentration was adjusted to 180-200 ng/mL. CsA was switched to oral administration when the patient's bowel function recovered.
Study NCT02677181 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CsA
Description: cyclosporine (3 mg/kg, q12h, i.v.) was used from day -9, and the concentration was adjusted to 180-200 ng/mL. CsA was switched to oral administration when the patient's bowel function recovered.
Study NCT02677181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Description: From day -9, 0.5 g of mycophenolate mofetil was administered orally from every 12 h, which was withdrawn on day +30 for MSD-PBSCT.
Study NCT02677181 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mycophenolate mofetil
Description: From day -9, 0.5 g of mycophenolate mofetil was administered orally from every 12 h, which was withdrawn on day +30 for MSD-PBSCT.
Study NCT02677181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: short-term methotrexate
Study NCT02677181 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: short-term methotrexate
Study NCT03574922 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Balance exercises
Description: Balance Exercises
Study NCT03574922 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Core Stabilization exercises
Description: Core Stabilization exercises
Study NCT05017259 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: calorie restriction diet
Description: The 7-day low-calorie diet contained 15.8 ± 0.4 kcal/kg/d in both trials, divided into three meals a day.
Study NCT05017259 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: calorie restriction diet
Description: The 7-day low-calorie diet contained 15.8 ± 0.4 kcal/kg/d in both trials, divided into three meals a day.
Study NCT04636242 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Skin Biopsy
Description: A Biopsy of the skin where the arthroscopic instrument will be placed, will be taken and sent to the microbiology lab for analysis
Study NCT01061736 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for sarilumab)
Description: Pharmaceutical form: solution for injection~Route of administration: subcutaneous
Study NCT01061736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (for sarilumab)
Description: Pharmaceutical form: solution for injection~Route of administration: subcutaneous
Study NCT01061736 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methotrexate
Description: Same weekly dose as received prior to enrollment
Study NCT01061736 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Same weekly dose as received prior to enrollment
Study NCT03594110 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: Taken daily with or without food
Study NCT04636242 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Skin Biopsy
Description: A Biopsy of the skin where the arthroscopic instrument will be placed, will be taken and sent to the microbiology lab for analysis
Study NCT04636242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 Aminolevulinic Acid + Phototherapy
Description: 5 aminolevulinic acid solution will be placed on the skin of the shoulder and the participant will receive Photodynamic therapy on the morning of surgery
Study NCT04583020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab
Description: Neoadjuvant Camrelizumab 200mg IV, adjuvant Camrelizumab 200mg IV (once every two weeks, until progress)
Study NCT04583020 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation
Description: 60Gy/30
Study NCT04583020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO during RT 75mg/m2/d; 4 weeks post RT 150-200mg/m2/d days 1-5, 4 weeks/cycle, 6 cycles
Study NCT02033330 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: phenolics form orange peel
Study NCT02033330 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: phenolics form orange peel
Study NCT03594110 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Description: Taken daily with or without food
Study NCT02063451 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Very Low Calorie Diet (VLCD)
Description: Very Low Calorie Diet (VLCD) using the HMR meal replacement (Health Management Resources, Boston, MA). Typically, individuals consume 850-1000 kilocalories per day until a targeted 15% reduction in body weight is achieved.